Drotrecogina alfa

• Autores: Carmen Blanco Bermejo, J. Carrera Hueso, Jaime E. Poquet Jornet, José Antonio Martín Conde, Francisco Javier Carrera Hueso
• Localización: Atención Farmacéutica, ISSN 1139-7357, Vol. 7, Nº. 4, 2005, págs. 288-295
• Idioma: español
• Títulos paralelos:
  • Drotrecogin alpha
• Texto completo no disponible (Saber más ...)
• Resumen

  • Sepsis associated with acute organic dysfunction is one of the first causes of mortality, in spite of an adequate antimicrobial treatment and the elimination of the infection's origin. Studies show that protein C's system anomalies are present in the largest number of patients with severe sepsis and they are associated with an increase in the risk of mortality. Activated protein C possesses antithrombotic, anti-inflammatory and profibrinolytic properties. Drotrecogin alpha (activated) is the recombinant activated protein C of plasma and improves the survival in patients with severe sepsis, even when it has as its main side effect the capability of increasing the risk of bleeding. Drug knowledge and its handling, as well as the selection and exclusion of patients susceptible of being treated, is going to be fundamental for its clinical efficiency